
    
      Subjects will receive 5 daily treatments per treatment week for 4 weeks (20 treatments).
      Patients who do not meet a 50% reduction of Hamilton Anxiety Rating Scale (HAM-A) score
      (non-responders) at 4 weeks will be offered 2 additional treatment weeks for up to 30
      treatments total.

      Subjects who qualify for enrollment will be followed and assessed using the: Mini
      International Neuropsychiatric Interview (MINI) for Axis 1, Montreal Cognitive Assessment
      (MoCA), Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D17),
      Generalized Anxiety Disorder 7-item (GAD-7), and Quick Inventory of Depressive Symptomatology
      Self Report (QIDS-SR16) patient reported scale. Treatment will be initiated on Day 1 of the
      study and will be continued for a minimum of 4 and a maximum of 6 weeks.
    
  